Edition:
United Kingdom

GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,664.60GBp
5:02pm BST
Change (% chg)

6.60 (+0.40%)
Prev Close
1,658.00
Open
1,657.40
Day's High
1,670.00
Day's Low
1,652.60
Volume
5,472,702
Avg. Vol
6,963,429
52-wk High
1,749.40
52-wk Low
1,408.80

About

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare... (more)

Overall

Beta: 1.03
Market Cap(Mil.): £86,295.03
Shares Outstanding(Mil.): 4,988.15
Dividend: 0.19
Yield (%): --

Financials

  GSK.L Industry Sector
P/E (TTM): 18.93 29.73 33.85
EPS (TTM): 0.91 -- --
ROI: 12.65 13.04 12.69
ROE: 124.83 14.12 17.13

AstraZeneca scores win in race to treat ovarian cancer

FRANKFURT AstraZeneca has made further headway in the race with larger competitor GlaxoSmithKline's to use a promising new class of drugs to treat ovarian cancer.

14 Aug 2019

AstraZeneca scores win in race to treat ovarian cancer

FRANKFURT, Aug 14 AstraZeneca has made further headway in the race with larger competitor GlaxoSmithKline's to use a promising new class of drugs to treat ovarian cancer.

14 Aug 2019

GSK ends development of Ebola vaccine, hands work to U.S. institute

LONDON British drugmaker GlaxoSmithKline is giving up its work on developing three potential vaccines against the deadly Ebola and Marburg viruses, despite an ongoing Ebola outbreak in Democratic Republic of Congo.

06 Aug 2019

GSK ends development of Ebola vaccine, hands work to U.S. institute

LONDON British drugmaker GlaxoSmithKline is giving up its work on developing three potential vaccines against the deadly Ebola and Marburg viruses, despite an ongoing Ebola outbreak in Democratic Republic of Congo.

06 Aug 2019

UPDATE 1-GSK ends development of Ebola vaccine, hands work to U.S. institute

LONDON, Aug 6 British drugmaker GlaxoSmithKline is giving up its work on developing three potential vaccines against the deadly Ebola and Marburg viruses, despite an ongoing Ebola outbreak in Democratic Republic of Congo.

06 Aug 2019

GSK hands work on potential Ebola vaccines to U.S. institute

LONDON, Aug 6 British drugmaker GlaxoSmithKline is handing over all its development work on three potential vaccines against the deadly Ebola and Marburg viruses despite an ongoing Ebola outbreak in Democratic Republic of Congo.

06 Aug 2019

GSK raises 2019 earnings expectations after standout quarter for Shingrix

GlaxoSmithKline beat second quarter profit expectations with the help of strong demand for its shingles vaccine, prompting the British drugmaker to forecast a smaller fall in profit this year than originally anticipated. | Video

24 Jul 2019

GSK raises 2019 earnings expectations after standout quarter for Shingrix

GlaxoSmithKline beat second quarter profit expectations with the help of strong demand for its shingles vaccine, prompting the British drugmaker to forecast a smaller fall in profit this year than originally anticipated. | Video

24 Jul 2019

WRAPUP 1-GSK raises 2019 earnings expectations after standout quarter for Shingrix

July 24 GlaxoSmithKline beat second quarter profit expectations with the help of strong demand for its shingles vaccine, prompting the British drugmaker to forecast a smaller fall in profit this year than originally anticipated.

24 Jul 2019

REFILE-UPDATE 1-GSK predicts smaller fall in 2019 profit after standout quarter for Shingrix

July 24 GlaxoSmithKline Plc on Wednesday forecast a smaller than previously estimated fall in full-year profit after the British drugmaker beat profit consensus for the second quarter due to demand for its fast-growing Shingles vaccine.

24 Jul 2019
Reuters.com is improving our Quote page. Click here to take a look and let us know what you think.

Earnings vs. Estimates